Skip to main content
SpringerLink
Log in

Is neopterin level a predictive and differential biomarker in patients with thyroid disorders?

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Neopterin production provides information about the extent of cellular immune activation. Measurement of neopterin levels may also provide predictive and prognostic information in patients with malignant thyroid diseases. In the present study, neopterin levels were investigated in patients with thyroid disorders (no.=68). Twenty-four patients had papillary thyroid cancers and the rest of them benign thyroid disorders. Results were compared with a healthy control group (no.=30). It was observed that there was a significant difference in neopterin levels between the control group and the thyroid disorders group (p<0.05). The mean neopterin levels in malignant and benign patients were also significantly different (p<0.05). Monitoring of urinary neopterin profile may be used in early diagnosis of papillary thyroid cancer. Neopterin seems to be a differential biomarker for malignant and benign thyroid disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Erdogan G, Erdogan MF, Emral M, et al. Iodine status and prevalence in Turkey before mandatory iodization. J Endocrinol Invest 2002, 25: 224–8.

    Article  PubMed  CAS  Google Scholar 

  2. Hiroshimaya T, Takahashi H, Yao K, et al. Clinical review of thyroid malignant tumor. Acta Otolaryngol Suppl 2002, 547: 85–7.

    Article  PubMed  Google Scholar 

  3. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 1985, 55: 805–28.

    Article  PubMed  CAS  Google Scholar 

  4. Ito Y, Hirokawa M, Jikuzono T, et al. Extranodal tumor extension to adjacent organs predicts a worse cause-specific survival in patients with papillary thyroid carcinoma. World J Surg 2007, 31: 1194–201.

    Article  PubMed  Google Scholar 

  5. Reibnegger G, Weiss G, Wachter H. Neopterin in malignant diseases. Tumour Marker Update 1992, 4: 101–3.

    Google Scholar 

  6. Altindag ZZ, Sahin G, Kansu E, Duru S. Urinary neopterin levels in patient with leukemia. New J Med Suppl 1995, 12: 29–32.

    Google Scholar 

  7. Yuksel O, Sahin TT, Girgin G, et al. Neopterin, catalase and superoxide dismutase in females with benign and malignant breast tumors. Pteridines 2007, 18: 132–8.

    Article  CAS  Google Scholar 

  8. Murr C, Bergant A, Widschwendter M, Heim K, Schröcksnadel H, Fuchs D. Neopterin is an independent prognostic variable in females with breast cancer. Clin Chem 1999, 45: 1998–2004.

    PubMed  CAS  Google Scholar 

  9. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002, 3: 175–87.

    Article  PubMed  CAS  Google Scholar 

  10. Berdowska A, Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Therap 2001, 26: 319–29.

    Article  CAS  Google Scholar 

  11. Fukuda A, Mazda T, Gyure WL, et al. A comparative study of urinary xanthopterin and neopterin in liver diseases. Eur J Clin Chem Clin Biochem 1993, 31: 129–34.

    PubMed  CAS  Google Scholar 

  12. Altindag ZZ, Baydar T, Isimer A, Sahin G. Neopterin as a new biomarker for the evaluation of occupational exposure to silica. Int Arch Occup Environ Health 2003, 76: 318–22.

    PubMed  CAS  Google Scholar 

  13. Baydar T, Engin AB, Aydin A, Sahin G. Effect of aluminum exposure on pteridine metabolism. Biol Trace Elem Res 2005, 106: 153–64.

    Article  PubMed  CAS  Google Scholar 

  14. Bjelakovic G, Jevtovic-Stoimenov T, Bjelakovic B, Stojanovic I. Biochemical functions and clinical importance of unconjugated pteridines. Facta Universitatis Med Biol 2004, 11: 49–52.

    Google Scholar 

  15. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin-Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984, 160: 310–6.

    Article  PubMed  CAS  Google Scholar 

  16. Reibnegger G, Fuchs D, Fuith LC, et al. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev 1991, 15: 483–90.

    PubMed  CAS  Google Scholar 

  17. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular activation in transplantation, inflammatory, infectious and malignant disease. Crit Rev Clin Chem 1992, 29: 307–41.

    CAS  Google Scholar 

  18. Kawasaki H, Watanabe H, Yamada S, Watanabe K, Suyama A. Prognostic significance of urinary neopterin levels in patients with hepatocellular carcinoma. Tohoku J Exp Med 1988, 155: 311–8.

    Article  PubMed  CAS  Google Scholar 

  19. Hoffmann G, Wirleitner B, Fuchs D. Potential role of immune system activation associated production of neopterin derivatives in humans. Inflamm Res 2003, 52: 313–21.

    Article  PubMed  CAS  Google Scholar 

  20. Wagner R, Hayatghebi S, Rosenkranz M, Reinwein D. Increased serum neopterin levels in patients with Graves’ disease. Exp Clin Endocrinol 1993, 101: 249–54.

    Article  PubMed  CAS  Google Scholar 

  21. Schomburg A, Grünwald F, Schultes B, Hotze A, Bender H, Biersack HJ. Are serum neopterin concentrations superior to other parameters in the differential diagnosis and prognostic assessment of Graves’ disease? Exp Clin Endocrinol Diabetes 1996, 104: 123–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Faculty of Medicine, Gazi University, Ankara, Turkey

    T. T. Sahin, O. Yuksel, K. Dikmen, C. Azili & F. Taneri

  2. Department of Toxicology, Faculty of Pharmacy, Hacettepe University, 06100, Ankara, Turkey

    G. Girgin, H. Sipahi & T. Baydar PhD

Authors
  1. T. T. Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Yuksel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Girgin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Sipahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Dikmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Azili
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Taneri
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T. Baydar PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Baydar PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sahin, T.T., Yuksel, O., Girgin, G. et al. Is neopterin level a predictive and differential biomarker in patients with thyroid disorders?. J Endocrinol Invest 32, 147–149 (2009). https://doi.org/10.1007/BF03345704

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345704

Key-words

Search

Navigation